Sterility failures hit compounded GLP-1s, NAD+ and sermorelin: a check-your-vial update

Compounded injections live outside the FDA approval system: pharmacies mix them under state and federal compounding rules, and sterility depends entirely on the pharmacy's process. When that process fails inspection, the remedy is a recall. A set of such recalls — covering compounded semaglutide and tirzepatide (the GLP-1 drugs), compounded NAD+, the peptide sermorelin, and Tri-Mix/Quad-Mix — appears in recent FDA Enforcement Reports and was summarized for patients in an October 18, 2026 health-news roundup drawing on the MedShadow Foundation's recall reporting.

Which products and pharmacies are named?

Per the MedShadow summary of the FDA Enforcement Reports: Carolina Infusion LLC (Ridgeland, South Carolina, a 503A pharmacy) — a Class II recall initiated September 10, 2026 covering compounded semaglutide, tirzepatide, their cyanocobalamin (B12) versions, Tri-Mix, Quad-Mix and sermorelin acetate, all for lack of sterility assurance, following an August 8–15, 2026 FDA inspection that produced a Form 483 with 10 items including inadequate sterilization and endotoxin testing. Houston RX LLC — compounded sermorelin (7 vials, 1 mg/mL), Class II, initiated September 25, 2026, after a Form 483 with 14 items. Apothecary Pharma LLC (Cary, North Carolina, a 503B outsourcing facility) — 22 vials of compounded tirzepatide (18 mg/mL) plus 1 vial of compounded NAD+ (200 mg/mL), Class II, initiated September 24, 2026, also for lack of sterility assurance. The same roundup separately lists compounded glutathione among recently announced recalls.

Why does a sterility recall matter more for injections than for pills?

Injected and infused products bypass the gut and skin barriers that filter much of what we swallow or apply. A vial with inadequate sterility assurance can carry bacteria or endotoxins — bacterial debris that triggers fever and inflammatory reactions — directly into tissue or bloodstream. That is the same failure mode behind this summer's compounded glutathione recalls, in which patients needed emergency care. Class II means the product may cause temporary or medically reversible harm; it is not the most severe class, but for elective wellness injections the risk-benefit math is unforgiving: the benefit is unproven, so any avoidable contamination risk dominates.

What should patients with compounded vials do?

Check the pharmacy name and lot on any compounded GLP-1, NAD+, sermorelin, glutathione or peptide vial against the FDA Enforcement Reports (published weekly) and ask the dispensing pharmacy directly whether your lot is affected. Do not use a vial from a recalled lot; contact the pharmacy about replacement or refund, and seek care promptly for fever, chills, or injection-site pain and redness after any compounded injection. And keep the broader context in view: compounded versions of approved drugs are not FDA-approved products, and NAD+ injections and IV drips remain unproven therapies — sterility is the floor, not the ceiling, of what to ask about.

Where the evidence stands

• Established: Compounded drugs are not FDA-approved; sterility depends on pharmacy process, and FDA Enforcement Reports document these Class II recalls (lack of sterility assurance) initiated in September 2026 after Form 483 inspection findings.
• Preliminary: Specific lots and counts as summarized by MedShadow from the Enforcement Reports: Carolina Infusion (initiated Sep 10, 2026; 10-item 483), Houston RX sermorelin (7 vials; Sep 25), Apothecary Pharma tirzepatide (22 vials) and NAD+ (1 vial) (Sep 24).
• Absent: Any evidence that compounded NAD+, sermorelin or glutathione injections improve mitochondrial function or health outcomes in people — the underlying therapies remain unproven regardless of sterility.